Australia's largest stock trading and investment forum Australia's #1 stock forum

NEA

Click for more information

0.00%

$2.10 nearmap ltd

Ann: H1 FY2018 Preliminary Results - Record Growth, page-36

First 36 Last

Share
Profile

Follow
birdman29

29,055 Posts.

487

15/01/18

05:44

Post #: 30297929
Share

Originally posted by Fatman8 ↑

Don't know why people are talking CR
seems to me the expenses will be one offs for R&D of oblique imagery & map New Software. We already learned fir every dollar spent in US & Oz we are making 95% 100% return, on that dollar, then reoccurring contracts after that. Add to that the conversion rates and bigger contract size in US & its looking pretty healthy.
Nearmap have always handled their money well.
The CR was when the 3D oblique imagery was in its infancy 2016.
Was wondering when they were going to spend this CR money. Seemed to be ages for them to spend any if it.
Really they have not spent anything of the CR money still 20 mill in the bank. and have managed on what they had in the bank from the 32 or 36 million from the stat mux patent.
What's been achieved with that 8 Million take AUD to USD conversation rates into this. Should see a healthy return without the need for another CR
The only way I see them needing more money is if they take on another country.

Expand

EQUITY RESEARCH
Information Technology
11th January 2018

NEA Price at posting: 67.5¢ Sentiment: Hold Disclosure: Held
22 Upvote

0 Great analysis

Reply

Top Stories

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

HotCopper Highlights: Your most watched and most discussed stocks this week

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Trump is President Again: What Does This Mean for Crypto?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

IMU

Imugene kicks off Australian trial for blood cancer treatment

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

First 36 Last

Add NEA (ASX) to my watchlist